Skip to Content

KedRAB FDA Approval History

FDA Approved: Yes (First approved August 23, 2017)
Brand name: KedRAB
Generic name: rabies immunoglobulin human
Dosage form: Injection
Company: Kamada Ltd. and Kedrion S.p.A.
Treatment for: Rabies Prophylaxis

KedRAB [rabies immunoglobulin (human)] is a human plasma derived anti-rabies immunoglobulin indicated for post-exposure prophylaxis (PEP) of rabies infection.

Development Timeline for KedRAB

Aug 25, 2017Approval FDA Approves KedRAB [rabies immune globulin (Human)] for Post-Exposure Prophylaxis of Rabies Infection
Sep  1, 2016Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.